FILING ANALYSIS · THURSDAY, NOVEMBER 12
Verrica Pharmaceuticals Inc. VRCA — 8-K: Results of Operations and Financial Condition
positive
Verrica Pharmaceuticals reported record Q3 revenue of $6.9 million, with YCANTH net product revenue up 57.9% year-over-year, and announced the completion of enrollment in the first pivotal trial for common warts, with topline data expected in Q1 2027. The company also unlocked access to $27.5 million in non-dilutive growth capital, extending its cash runway through data readouts for both common wa
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →